Allopurinol in Patients With Refractory Angina to Improve Ischemic Symptoms
Status:
Recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
Despite numerous advances in medical treatment and revascularization procedures for the
treatment of patients with stable angina, debilitating symptoms that are unresponsive to
conventional therapy may occur in patients unsuitable for revascularization, a condition
known as refractory angina. Allopurinol, a methylxanthine oxidase inhibitor, is widely used
in the treatment of gout and asymptomatic hyperuricemia. On the other hand, the anti-ischemic
effects of allopurinol have been the subject of increasing interest. Therefore, the
investigators will study the safety and efficacy of allopurinol in alleviating ischemic
symptoms in patients with refractory angina already on optimal medical therapy.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Ministry of Health, Brazil
Collaborators:
Fundação de Amparo à Pesquisa do Estado de São Paulo InCor Heart Institute